Clinical outcome for chemoradiotherapy in carcinoma of the cervix.
AffiliationDepartment of Clinical Oncology, Christie Hospital, Manchester, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractAIMS: Two recent meta-analyses have shown a survival advantage for the addition of concurrent chemotherapy to radiotherapy in the treatment of cervical cancer. However, there is insufficient information available on late toxicity and few data from UK practice. The aims of this study were to examine treatment outcomes (survival and toxicity) in patients with cervical cancer treated with chemoradiation and to compare these with outcomes in patients treated with radiation alone. MATERIALS AND METHODS: Between July 2000 and December 2003, 75 patients with cervical cancer were treated with chemoradiation. Case notes were reviewed retrospectively. Acute and late toxicity were recorded, with late toxicity graded using the Franco-Italian glossary. The median age was 47 years. All patients were staged with examination under anaesthesia and magnetic resonance imaging scans. Forty-two patients were treated with concurrent chemoradiation alone and 33 patients were treated with a combination of neoadjuvant and concurrent chemoradiation. This was due to waiting list problems. The chemotherapy used was cisplatin 40 mg/m(2) weekly with radiotherapy, (the neoadjuvant dose was 60 mg/m(2) 3 weekly). External beam radiotherapy was given to the pelvis (40-45 Gy/20 fractions/4 weeks) followed by low dose rate brachytherapy (22.5-32.5 Gy to point A). Patients who were unable to have brachytherapy were given an external beam boost (15-20 Gy/8-10 fractions). RESULTS: The 3-year overall survival rate was 70%, with an estimated 5-year overall survival rate of 60%. The 3-year disease-free survival was 63.6%, with an estimated 5-year disease-free survival rate of 55%. Compared with the cohort of 183 patients from the Christie Hospital in a 1993 audit, there was a trend towards improved overall survival from 49 to 60% (P=0.06), which may become significant with longer follow-up. There were seven patients (9.3%) with grade 3 toxicity and no cases of grade 4 toxicity. In comparison with patients treated in the 1993 audit, the late toxicity rate has increased from 3.4 to 9.3%, but this was not statistically significant (P=0.14). CONCLUSION: There was a trend towards improved survival with concurrent chemoradiation in this cohort of patients that may become significant with longer follow-up.
CitationClinical outcome for chemoradiotherapy in carcinoma of the cervix. 2009, 21 (1):49-55 Clin Oncol (R Coll Radiol)
JournalClinical Oncology (R Coll Radiol)
- Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy.
- Authors: Sood BM, Gorla G, Gupta S, Garg M, Deore S, Runowicz CD, Fields AL, Goldberg GL, Anderson PS, Vikram B
- Issue date: 2002 Jul 1
- [Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion].
- Authors: Lerouge D, Touboul E, Lefranc JP, Uzan S, Jannet D, Moureau-Zabotto L, Genestie C, Antoine M, Jamali M
- Issue date: 2004 Jun
- Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy.
- Authors: Sood BM, Gorla GR, Garg M, Anderson PS, Fields AL, Runowicz CD, Goldberg GL, Vikram B
- Issue date: 2003 Apr 1
- Radiochemotherapy for patients with locally advanced cervical cancer: early results.
- Authors: Ozsaran Z, Yalman D, Yürüt V, Aras A, Ozsaran A, Hanhan M, Haydaroğlu A
- Issue date: 2003
- Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery +/- intraoperative electron beam radiotherapy in locally advanced cervical cancer.
- Authors: Jurado M, Martínez-Monge R, García-Foncillas J, Azinovic I, Aristu J, López-García G, Brugarolas A
- Issue date: 1999 Jul